Long-term study of ACP-204 for psychosis linked to Alzheimer's disease
Checks the long-term safety of ACP-204 in older adults with Alzheimer's psychosis.
Plain-language title generated from the registry record
Registry title: ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Key facts
- Where
- Belgrade, Gornja Toponica, Kovin, Kragujevac, and Niš, SerbiaSee the 9 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 95 years old?
Source: NCT06194799, who can take part
Where in Serbia
- Clinical Center Dr Dragisa Misovic DedinjeBelgrade, SerbiaNo longer taking part
- Institute of Mental HealthBelgrade, SerbiaNo longer taking part
- Special Hospital for Cerebrovascular Diseases Sveti SavaBelgrade, SerbiaNo longer taking part
- Special Hospital for Psychiatric DiseasesGornja Toponica, SerbiaNo longer taking part
- Special Hospital for Psychiatric Diseases KovinKovin, SerbiaNo longer taking part
- Janjic University Clinical Center KragujevasKragujevac, SerbiaNo longer taking part
- Jovanovic University Clinical Centre of KragujevacKragujevac, SerbiaNo longer taking part
- Petrovic University Clinical Center KragujevacKragujevac, SerbiaNo longer taking part
- University Clinical Center NISNiš, SerbiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ACADIA Pharmaceuticals Inc.
- Trial code
- NCT06194799EU 2023-507351-29-00
- Record updated
- 4 November 2026
- Original description
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.Read full original descriptionShow less
A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
Inclusion: Subject has successfully completed ACP-204-006 study; Male or female (age 55 to 95 years old): female must be of non-childbearing potential, male must take appropriate contraceptive method if partner has childbearing potential; Subject has a designated study partner/caregiver; Subjects are able to complete all study visits with a study partner/caregiver; Signed inform consent form with a caregiver or legal representative.
Exclusion: Requires treatment with a medication prohibited by the protocol; Is in hospice and receiving end-of-life palliative care, or has become bedridden; Unstable clinically significant medical condition other than AD; Any medical condition that in the opinion of the investigator may affect safety or ability to complete the study; Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.